

63	<b>GUIDELINE FOR THE MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE – 2011 UPDATE</b>
63	ABSTRACT
64	1. DEFINITION
64	2. EPIDEMIOLOGY OF COPD
64	3. RISK FACTORS
64	3.1 Host
64	3.2 Environment
65	3.3 Infections
65	3.4 Socioeconomic status
65	3.5 Nutrition
65	4. AIM OF THIS GUIDELINE
65	5. RECOGNITION OF DISEASE (EARLY DIAGNOSIS AND STAGING OF SEVERITY)
66	5.1 Spirometry
66	5.2 Detection of airflow obstruction
66	5.3 Assessment of reversibility with short-acting bronchodilators
66	5.4 Assessment of severity of COPD
66	5.5 Monitoring disease progression
66	5.6 Chest radiography
66	6. PREVENTION OF DISEASE PROGRESSION (INCLUDING SMOKING CESSATION)
66	6.1 Smoking cessation programmes
67	6.2 Features that contribute to a successful programme
67	7. ALLEVIATION OF BREATHLESSNESS AND IMPROVEMENT IN EFFORT TOLERANCE (TREATMENT OF AIRFLOW OBSTRUCTION)
67	7.1 Bronchodilators
67	7.2 Inhaled corticosteroids
68	7.3 Oral corticosteroids
68	7.4 Newer phosphodiesterase inhibitors
68	7.5 Mucolytics and mucokinetic agents
68	7.6 Chest physiotherapy
68	7.7 Venesection
68	7.8 Assessment of response to therapy
68	8. PULMONARY REHABILITATION AND EDUCATION (IMPROVING QUALITY OF LIFE)
68	9. PREVENTION AND TREATMENT OF ACUTE EXACERBATIONS OF COPD
68	9.1 Definition, natural history and diagnosis of exacerbations
68	9.2 Prevention of exacerbations
68	9.3 Management of exacerbations



**Editor**

DANIEL J NCAYIYANA

**Managing Editor**

J P DE V VAN NIEKERK

**Deputy Editor**

BRIDGET FARHAM

**Assistant Editor**

EMMA BUCHANAN

**Technical Editors**

MARIJKE MAREE

ROBERT MATZDORFF

PAULA VAN DER BIJL

**News Editor**

CHRIS BATEMAN

Tel. (021) 681-7200

**Head of Publishing**

ROBERT ARENDSE

**Production Manager**

EMMA COUZENS

**Professional Advertising**

BELINDA DOYLE

Tel. (021) 681-7200

E-mail: belinda@hmpg.co.za

**Art Director**

SIOBHAN TILLEMANS

**DTP & Design**

TRAVIS ARENDSE

CLINTON MARK GRIFFIN

**Online Manager**

GERTRUDE FANI

**Distribution Manager**

EDWARD MACDONALD

**Advertising Enquiries**

**SALES DIRECTOR:** DIANE SMITH

Tel. (012) 481-2069

Email: dianes@samedical.org

**Sales Team**

LISA REID, AZAD YUSUF,

KEITH HILL, ANDREW CROSS

VALERIE HOWARD, SALIE PETERSEN

**HMPG Board of Directors**

M RAFF (*Chair*)

R ABBAS

M LUKHELE

D J NCAYIYANA

J P DE V VAN NIEKERK

M VELLER

**Associate Editors**

Q ABDOOL KARIM

A DHAI

N KHUMALO

R C PATTINSON

A ROTHBERG

A A STULTING

J SURKA

B TAYLOR

ISSN 0256-9574

Website: [www.hmpg.co.za](http://www.hmpg.co.za)

Journal: [www.samj.org.za](http://www.samj.org.za)



69	10. PREVENTION AND TREATMENT OF COMPLICATIONS
69	10.1 The management of right heart failure
69	10.2 Pneumothorax
69	10.3 Long-term oxygen therapy (LTOT)
70	10.4 Palliative symptomatic oxygen therapy
70	10.5 Additional considerations
71	REFERENCES
72	Appendix A. Process of guideline revision
72	Appendix B. The 6-minute walk test (6MWT)
73	Appendix C. Antibiotic use in exacerbations of COPD
73	Appendix D. Pulmonary rehabilitation

## Contents listed in

INDEX MEDICUS (MEDLINE).  
EXCERPTA MEDICA (EM BASE).  
BIOLOGICAL ABSTRACTS (BIOSIS).  
SCIENCE CITATION INDEX  
(SCISEARCH). CURRENT  
CONTENTS/CLINICAL MEDICINE

*Unless otherwise stated, opinions expressed in the editorial columns of the SAMJ should not be taken as reflecting official South African Medical Association policy. The appearance of advertising in the Association's publications does not denote a guarantee or an endorsement by the Association of the products or the claims made for the products by the manufacturers.*

## Subscription rates

**Local subscriptions R852.00 p.a.**

**Foreign subscriptions R1 920.00 p.a.**

**Single copies R75.00**

Members of the Association receive the SAMJ only on request, as part of their membership benefit.

Subscriptions: Tel. (012) 481-2071  
E-mail: [members@samedical.org](mailto:members@samedical.org)

**The SAMJ is published  
monthly by the  
Health and Medical Publishing Group  
(Pty) Ltd,  
Co registration 2004/0220 32/07,  
a subsidiary of SAMA.**

**28 Main Road (Cnr Devonshire Hill  
Road), Rondebosch, 7700**

**Please submit all letters and articles  
for publication online  
at [www.samj.org.za](http://www.samj.org.za)  
Tel. (021) 681-7200.**

**Fax (021) 685-1395. E-mail:  
[publishing@hmpg.co.za](mailto:publishing@hmpg.co.za)  
Website: [www.samedical.org](http://www.samedical.org)**

© Copyright: Health and Medical Publishing Group (Pty) Ltd, a subsidiary of the South African Medical Association  
Use of editorial material is subject to the Creative Commons Attribution – Noncommercial Works License. <http://creativecommons.org/licenses/by-nc/3.0>

PRINTED BY TANDYM PRINT



## Guideline for the management of chronic obstructive pulmonary disease – 2011 update

M S Abdool-Gaffar, A Ambaram, G M Ainslie, C T Bolliger, C Feldman, L Geffen, E M Irusen, J Joubert, U G Laloo, T T Mabaso, K Nyamande, J O'Brien, W Otto, R Raine, G Richards, C Smith, D Stickells, A Venter, S Visser, M Wong

**Objective.** To revise the South African Guideline for the Management of Chronic Obstructive Pulmonary Disease (COPD) based on emerging research that has informed updated recommendations.

**Key points.**

1. Smoking is the major cause of COPD, but exposure to biomass fuels and tuberculosis are important additional factors.
2. Spirometry is essential for the diagnosis and staging of COPD.
3. COPD is either undiagnosed or diagnosed too late, so limiting the benefit of therapeutic interventions; performing spirometry in at-risk individuals will help to establish an early diagnosis.
4. Oral corticosteroids are no longer recommended for maintenance treatment of COPD.
5. A therapeutic trial of oral corticosteroids to distinguish corticosteroid responders from non-responders is no longer recommended.
6. Primary and secondary prevention are the most cost-effective strategies in COPD. Smoking cessation as well as avoidance of other forms of pollution can prevent disease in susceptible individuals and ameliorate progression. Bronchodilators are the mainstay of pharmacotherapy, relieving dyspnoea and improving quality of life.
7. Inhaled corticosteroids are recommended in patients with frequent exacerbations and have a synergistic effect with bronchodilators in improving lung function, quality of life and exacerbation frequency.
8. Acute exacerbations of COPD significantly affect morbidity, health care units and mortality.
9. Antibiotics are only indicated for purulent exacerbations of chronic bronchitis.
10. COPD patients should be encouraged to engage in an active lifestyle and participate in rehabilitation programmes.

**Options.** Treatment recommendations are based on the following: annual updates of the Global Obstructive Lung Disease (GOLD),

initiative, that provide an evidence-based comprehensive review of management; independent evaluation of the level of evidence in support of some of the new treatment trends; and consideration of factors that influence COPD management in South Africa, including lung co-morbidity and drug availability and cost.

**Outcome.** Holistic management utilising pharmacological and non-pharmacological options are put in perspective.

**Evidence.** Working groups of clinicians and clinical researchers following detailed literature review, particularly of studies performed in South Africa, and the GOLD guidelines.

**Benefits, harms and costs.** The guideline pays particular attention to cost-effectiveness in South Africa, and promotes the initial use of less costly options. It promotes smoking cessation and selection of treatment based on objective evidence of benefit. It also rejects a nihilistic or punitive approach, even in those who are unable to break the smoking addiction.

**Recommendations.** These include primary and secondary prevention; early diagnosis, staging of severity, use of bronchodilators and other forms of treatment, rehabilitation, and treatment of complications. Advice is provided on the management of acute exacerbations and the approach to air travel, prescribing long-term oxygen and lung surgery including lung volume reduction surgery.

**Validation.** The COPD Working Group comprised experienced pulmonologists representing all university departments in South Africa and some from private practice, and general practitioners. Most contributed to the development of the previous version of the South African guideline.

**Guideline sponsor.** The meeting of the Working Group of the South African Thoracic Society was sponsored by an unrestricted educational grant from Boehringer Ingelheim and Glaxo-Smith-Kline.

*S Afr Med J* 2011; 101: 61-73.

*Pulmonologist in private practice, Amanzimtoti*

**M S Abdool-Gaffar**, MB ChB, FCP

*Department of Pulmonology and Critical Care, Inkosi Albert Luthuli Hospital, Durban*

**A Ambaram**, MB BCH, DipPEC (SA), FCP (SA), Cert Pulm (SA), FCCP

*Respiratory Clinic, University of Cape Town and Groote Schuur Hospital*

**G M Ainslie**, MB ChB, FRCP

**R Raine**, MB ChB, MMed (Med), FCP (SA)

*Division of Pulmonology, Department of Medicine, Stellenbosch University and Tygerberg Academic Hospital, Tygerberg*

**C T Bolliger**, MD, PhD, BSc (Hons) (Epidem)

**E M Irusen**, MB ChB, FCP (SA), PhD

*Division of Pulmonology, Charlotte Maxeke Johannesburg Academic Hospital and University of the Witwatersrand*

**C Feldman**, MB BCH, DSc, PHD, FRCP, FCP (SA)

**Corresponding author:** M Abdool Gaffar (docsabs@gmail.com)

*Doctor in private practice, Cape Town*

**L Geffen**, MB ChB

*Division of Pulmonology, Department of Medicine, Stellenbosch University*

**J Joubert**, FCP (SA), MD

*Department of Pulmonology and Critical Care, Nelson R Mandela School of Medicine, University of KwaZulu-Natal and Inkosi Albert Luthuli Hospital, Durban*

**U G Laloo**, MB ChB, MD, FCP (SA), DOH, FCCP, FRCP

*Doctor in private practice, Durban*

**T T Mabaso**, MB ChB

*Department of Pulmonology and Critical Care, Nelson R Mandela School of Medicine, University of KwaZulu-Natal*

**K Nyamande**, FCP MD

*Pulmonologist in private practice, Cape Town*

**J O'Brien**, MB ChB, FCP (SA)

*Department of Internal Medicine, University of the Free State, Bloemfontein*

**W Otto**, MB ChB, MMed (Int)

Division of Intensive Care, Charlotte Maxeke Johannesburg Academic Hospital and University of the Witwatersrand

**G Richards**, MB BCh, PhD, FCP (SA), FRCP

Morningside Mediclinic, Sandton

**C Smith**, MB BCh, FCP (SA), MMed (Int Med), FCCP

Pulmonologist in private practice, Port Elizabeth

**D Stickells**, MB ChB, Dip Obst (SA), FCP (SA)

Pulmonologist in private practice, Pretoria

**A Venter**, MB ChB, Dip PEC (SA), DTMH (Wits), FCP (SA), Cert Pul (SA), BSc (Hons) (Med)

University of Pretoria and Steve Biko Academic Hospital

**S Visser**, MB ChB, M Med (Int Med), PhD (Imm)

Division of Pulmonology, Chris Hani Baragwanath Hospital and University of the Witwatersrand

**M Wong**, MB BCh, FCP (SA), FCCP, FRCP (Lond)

Chronic obstructive pulmonary disease (COPD) is a significant cause of death and disability in both developed and developing countries. It is increasing in frequency and demands increasing utilisation of healthcare resources. Cigarette smoking remains the major cause of COPD but, in developing countries, biomass fuel smoke and tuberculosis are important additional causes.

This revised guideline is based on the following premises: (i) COPD is an inflammatory disorder, and (ii) while COPD is associated with partial reversibility of the airflow limitation using simple spirometry, modern treatment results in significant symptomatic improvement in quality of life (QOL) and morbidity.

## 1. Definition

COPD is a disease state resulting from an abnormal inflammatory response of the lungs to irritant particles and gases, with resultant progressive airflow limitation that is partially reversible. It is associated with lung hyperinflation and systemic effects. The pathological correlates are chronic bronchitis and emphysema.<sup>1,2</sup>

## 2. Epidemiology of COPD

COPD is one of the leading causes of morbidity and mortality in the world. It is estimated that there are currently over 280 million cases in the world, a significant proportion of whom are undiagnosed. The prevalence of COPD is projected to rise owing to increased exposure to risk factors and population ageing.<sup>3,4</sup> A recent meta-analysis of 26 COPD studies in 28 countries reported a pooled prevalence estimate of 8.9%.<sup>5</sup>

The Burden of Obstructive Lung Disease (BOLD) study<sup>6</sup> that investigated the prevalence of COPD in various countries showed that COPD prevalence varied considerably in different countries, with a range of 6 - 19% for Stage  $\geq 2$  COPD (clinically significant disease) and 12 - 26% for Stage  $\geq 1$  COPD. South Africa had the highest prevalence of stage  $\geq 2$  COPD (19% overall, 22% male and 17% female), which may be greater than the general South African prevalence because of the higher incidence of smoking, occupational dust exposure, indoor pollution and prior tuberculosis in the area studied. Unlike other chronic diseases, COPD mortality for both men and women is increasing. The Global Burden of Disease Study has projected that COPD, which was ranked 6th as the cause of death in 1990, will become the third leading cause of death by 2020.<sup>7,8</sup>

## 3. Risk factors

The prevalence of COPD is generally directly related to the prevalence of tobacco smoking, but other factors are also involved. The risk for COPD results from a host-environment interaction; the factors are shown in Table I.

**Table I. Risk factors for the development of COPD**

<b>A. Host</b>
1. Genes (e.g. alpha-1 protease inhibitor deficiency)
2. Age
3. Gender
4. Lung growth and development
<b>B. Environment</b>
Inhalational exposure:
1. tobacco smoke
2. cannabis
3. occupational dusts and chemicals
4. indoor air pollution (heating/cooking with biomass fuels)
5. outdoor air pollution
<b>C. Infections</b> (e.g. childhood respiratory infection, TB, HIV)
<b>D. Socio-economic status</b>
<b>E. Nutrition</b>

### 3.1 Host

#### Genetic

The genetic risk factor that is best documented is the hereditary deficiency of alpha-1 protease inhibitor.<sup>9</sup> There is also an increased risk of airflow obstruction in the smoking siblings of patients with severe COPD, suggesting that other genetic factors are involved.<sup>10</sup> Genes associated with COPD susceptibility in smokers are increasingly being identified.<sup>11</sup>

#### Age

COPD prevalence increases with age, but this probably relates more to the increased cumulative burden of exposure to risk factors (smoking, pollution, infection, etc.) than age *per se*.<sup>12,13</sup>

#### Gender

COPD prevalence and mortality is greater among men than women, and reflects previous smoking patterns. The prevalence is now equalising in developed countries. Women may be more susceptible than men to the effects of tobacco smoke.<sup>14</sup>

#### Lung growth and development

Poor lung growth owing to problems *in utero* and exposure during childhood is associated with airflow obstruction in adulthood.<sup>15,16</sup>

### 3.2 Environment

#### Inhalational exposure

##### Tobacco smoke

COPD is more common in smokers and ex-smokers than in non-smokers. Cigarette smokers have more respiratory symptoms, lung function abnormalities, decline in FEV<sub>1</sub>, and COPD mortality than non-smokers. The starting age, total pack-years smoked and current smoking status are predictive of COPD morbidity and mortality.<sup>17</sup> The annual decline of FEV<sub>1</sub> in smokers varies from 55 - 100 ml/year v. about 30 ml/yr in non-smokers.<sup>18</sup> However, not all smokers develop clinically significant COPD so genetic factors must modify risk.<sup>19</sup> The oft-quoted figure of only 15% of smokers developing COPD is probably an under-estimate.<sup>20</sup> Pipe and cigar smokers have greater COPD morbidity and mortality rates than non-smokers, although their rates are lower than those for cigarette smokers.

Passive or environmental tobacco smoke (ETS) may also contribute to COPD.<sup>21,22</sup> Smoking during pregnancy may predispose to COPD by decreasing lung growth and development in the fetus.<sup>23</sup>

**Cannabis**

Smoking cannabis is associated with a dose-related airflow obstruction.<sup>24</sup> One cannabis joint is equivalent to 2.5 - 5 tobacco cigarettes.

**Occupational dusts and chemicals**

Occupational dust and chemical exposure is an independent cause of COPD.<sup>25</sup> The large population-based NHANES III (National Health and Nutrition Examination Survey) utilising spirometry in almost 10 000 adults estimated that the fraction of COPD attributable to work was 19% overall and 31% among never-smokers.<sup>26</sup>

**Indoor air pollution**

The burning of biomass and fossil fuels (wood, animal dung, crop residues and coal) in open fires or poorly-functioning stoves in poorly-ventilated spaces leads to very high levels of indoor air pollution. Almost half the world's population, and 90% of rural families (including >20 million in South Africa), use biomass and coal as their main source of energy for cooking and heating.<sup>27,28</sup> Several case-control and community-based studies have shown that this is associated with an increased risk for COPD in developing countries, especially among non-smoking women.<sup>29-31</sup> It is estimated that 2 million women and children die globally in consequence each year.<sup>7</sup>

**Outdoor air pollution**

Air pollution, mainly from motor vehicle emissions in cities and biomass smoke (from bush and forest fires), is associated with loss of lung function.<sup>32-34</sup>

**3.3 Infections**

Childhood respiratory infections are associated with reduced lung function and increased respiratory symptoms in adulthood.<sup>35</sup> Several studies have shown that previous pulmonary tuberculosis may lead to COPD.<sup>36-39</sup> HIV infection has been shown to accelerate the onset of smoking-related emphysema.<sup>40</sup> In addition, viral and bacterial infections may contribute to the pathogenesis and progression of COPD.<sup>41</sup>

**3.4 Socioeconomic status**

There is a higher prevalence of COPD among the lower socioeconomic strata,<sup>42</sup> but this probably reflects increased exposure to smoking, indoor and outdoor air pollution, susceptibility to infections and poor nutrition.

**3.5 Nutrition**

The role of nutrition as an independent risk factor for the development of COPD is unclear. Severe malnutrition has been associated with emphysema.<sup>43</sup>

**4. Aim of this guideline**

The purpose of this guideline is to improve the care of patients with COPD at all levels of the health system in South Africa and to provide information that will assist in recognising and appropriately treating this common condition (Table II).<sup>44,45</sup>

**Table II. Goals of management of COPD**

1. Recognition of disease (early diagnosis and staging of severity)
2. Prevention of disease progression (including smoking cessation)
3. Alleviation of breathlessness and improvement in effort tolerance (treatment of airflow obstruction)
4. Pulmonary rehabilitation and education (improving quality of life)
5. Prevention and treatment of exacerbations
6. Prevention and treatment of complications
7. Reduction in mortality

**5. Recognition of disease (early diagnosis and staging of severity)**

The diagnosis of COPD should be considered in any patient with chronic progressive dyspnoea and/or chronic cough (with or without sputum production) with a smoking history of more than 10 pack-years and/or other risk factors for COPD.

Correct diagnosis, and in particular the differentiation of COPD from asthma, is important to ensure correct treatment. Clinical features that assist in the diagnosis of each condition are outlined in Table III. Early detection of COPD and effective smoking cessation interventions slow the decline in pulmonary function and may alter the natural history.

**Table III. Distinguishing features of COPD and asthma**

**Features suggesting a diagnosis of COPD**

- Persistent unremitting dyspnoea, wheeze and productive cough despite treatment
- A long history of smoking or exposure to other risk factors
- Slow progression
- Hyperinflation and abnormal spirometry that persist during a stable phase of the disease
- Cyanosis

**Features that suggest the presence of asthma**

- Young age at onset
- Presence of atopy and/or allergic rhinitis
- Diurnal and day-to-day variation and seasonal variability
- Marked improvement in lung function after a bronchodilator and/or a 2-week trial of systemic steroids

**Additional considerations in the diagnosis of asthma and COPD**

- Asthma and COPD may co-exist, and distinguishing them may be difficult
- Breathlessness occurs late in COPD
- Asthmatics who smoke may have an accelerated decline in lung function

**Table IV. Medical Research Council dyspnoea scale**

Grade	Description
1	Not troubled by breathlessness except with strenuous exercise
2	Troubled by shortness of breath when hurrying on the level or walking up a slight hill
3	Walks slower than people of the same age on the level because of breathlessness or has to stop for stop for breath when walking at own pace
4	Stops for breath after walking about 100 m or after a few minutes on the level
5	Too breathless to leave the house or breathless when dressing or undressing

Clinical evaluation should include a history of exposure to tobacco smoking and other risk factors, an assessment of breathlessness (e.g. the MRC dyspnoea scale (Table IV)), the occurrence and severity of exacerbations, and co-morbid conditions that could complicate management. Physical examination may reveal signs of hyperinflation and airway obstruction but may be normal. Co-morbid conditions should also be sought.

## 5.1 Spirometry

Spirometry is essential for the detection, assessment and management of patients with COPD. It must be performed by adequately trained persons using a spirometer of approved standard and quality that is calibrated frequently. Measurements used in the diagnosis of COPD are FEV<sub>1</sub>, FVC and FEV<sub>1</sub>/FVC% pre- and post-bronchodilator.

## 5.2 Detection of airflow obstruction

The presence of an FEV<sub>1</sub>/FVC ratio of less than 70% confirms the presence of airflow obstruction. The FEV<sub>1</sub> is usually reduced (less than 80% of predicted value), and is used as a measure of severity. Most patients with symptomatic COPD have a reduced FEV<sub>1</sub>, but many patients with significantly reduced FEV1 have no symptoms.

## 5.3 Assessment of reversibility with short-acting bronchodilators

Spirometry should be performed before, and 20 minutes after, 4 puffs of a short-acting beta-2 agonist bronchodilator (e.g. salbutamol, fenoterol or terbutaline). An improvement in FEV<sub>1</sub> ≥12% from baseline and ≥200 ml indicates significant reversibility. This is compatible with asthma but is also seen in many patients with COPD. However, in general, the larger the improvement, the greater the likelihood that the diagnosis is asthma, especially with the clinical profile borne in mind (Table III).

## 5.4 Assessment of severity of COPD

To establish the severity of airflow obstruction, FEV<sub>1</sub> is expressed as a percentage of predicted values. The European Community for Steel and Coal (ECSC) (based on surveys performed in Europe)<sup>46</sup> or the NHANES III reference equations<sup>47</sup> are recommended for routine use in South Africa. Ethnic differences (amounting to approximately 12% lower values for FVC in Africans or African-Americans) have been demonstrated in some series, and a correction factor (multiplication of the spirometric value by 0.9) should be applied. Measurement of peak expiratory flow (PEF), while helpful in asthma, is not an appropriate

test for diagnosing and evaluating the severity of COPD and does not distinguish obstructive from restrictive lung disease. The assessment of severity of COPD is based on spirometric measures and clinical indicators including severity of dyspnoea, functional impairment and 6-minute walking distance (6MWD).<sup>48</sup> Grading of severity is used for prognostication and for selecting treatment. Details of the grades of severity are provided in Table V.

**TABLE V. Staging of COPD (FEV<sub>1</sub>/FVC <70%)**

	Stage 1 Mild	Stage 2 Moderate	Stage 3 Severe*	Stage 4 Very severe*
FEV <sub>1</sub> after bronchodilator	≥80%	50 - 80%	30 - 50%	<30%
Dyspnoea	MRC 2	MRC 3 - 4	MRC 5	MRC 5
6MWD	>600 m	200 - 600 m		<200 m

\*Also severe if repeated hospitalisation for exacerbations and respiratory or right heart failure.

## 5.5 Monitoring disease progression

COPD progresses slowly over years. More rapid deterioration suggests an acute exacerbation or alternative diagnosis e.g. asthma, cardiac failure and pneumothorax. Progression of the disease could be monitored using the parameters in Table V, but serial measurement of FEV<sub>1</sub> alone is probably most practical.

## 5.6 Chest radiography

A chest radiograph may show evidence of hyperinflation but frequently appears normal. It is also useful for detecting additional disease.

## 6. Prevention of disease progression (including smoking cessation)

Avoidance of occupational and environmental pollution, including passive or 'side-stream' tobacco smoke exposure is important, particularly in susceptible persons: pregnant women, infants and children, persons with alpha-1 protease inhibitor deficiency, and those with COPD.

Smoking cessation is the only measure that has been shown to slow the progression of COPD, and is one of the most cost-effective interventions in health care.<sup>49</sup> All smokers must be encouraged to stop smoking. Health care workers should be familiar with smoking cessation measures and promote these among their patients.<sup>50</sup> The advantages of cessation include: (i) slowing of the rate of decline of lung function (a small initial improvement in spirometry occurs in some), (ii) improved oxygen transport in blood, through reductions in carboxyhaemoglobin and blood viscosity, (iii) reduced tendency to thrombosis, (iv) improvements in appetite, body mass, muscle strength and exercise tolerance, (v) possible improved efficacy of some classes of drugs used in COPD, and (vi) delayed development of respiratory failure and cor pulmonale.

## 6.1 Smoking cessation programmes

There are many smoking cessation methods. Many are behavioural in approach, but some are pharmacological and involve gradual weaning from nicotine via nicotine replacement, with or without mood modifiers to counteract the negative effects of withdrawal. Many interventions show impressive short-term results, but long-term abstinence (defined as cessation without relapse for 12 months) occurs in <30% of patients

(for most methods, only 15 - 20%). Factors associated with poor success include heavy smoking and relapse within the first 2 weeks.

## 6.2 Features that contribute to a successful programme

6.2.1 At an initial in-depth interview, discuss the patient's smoking habits and previous quit attempts. The 5 'A's' are an increasingly used memory aid for counseling smokers:

- 'Ask' do you smoke?
- 'Advise' to quit.
- 'Assess' the willingness to quit.
- 'Assist' (aid) the patient to quit (provide counseling and medication).
- 'Arrange' follow-up contact.

6.2.2 Cessation advised repeatedly by a doctor.

6.2.3. Abrupt cessation rather than gradual smoking reduction, with agreement on a quit date and provision of support for adherence to the commitment (by clinical visit or phone call). For recalcitrant smokers, reduction is possible and enhances subsequent cessation.

6.2.4. Reinforcement and follow-up.

6.2.5. There are three medications for smoking cessation: (i) nicotine replacement therapy (NRT) with 4 approved formulations: gum, patch, sublingual tablets and an oral spray, (ii) Bupropion, an antidepressant and (iii) Varenicline, a newly developed partial nicotine agonist. These medications are mostly used as single treatments but, for more dependent smokers, combinations of more than 1 NRT or NRT with Bupropion have been shown to be effective.

## 7. Alleviation of breathlessness and improvement in effort tolerance (treatment of airflow obstruction)

### 7.1 Bronchodilators

Bronchodilators form the mainstay of the treatment of COPD, for which inhaled beta-2 agonists, inhaled anticholinergics and oral theophyllines are all effective. Individuals vary in their responsiveness to each, and combinations may have additive effects.<sup>51-53</sup> Commence treatment in symptomatic patients with an inhaled short-acting bronchodilator on a PRN basis. Thereafter, increase treatment stepwise to include inhaled long-acting bronchodilators, slow-release theophylline and inhaled corticosteroids (ICS) in various combinations (see Fig. 1).

#### 7.1.1 Inhaled short-acting beta-2 agonists

These agents have a rapid onset of action. Examples include salbutamol, fenoterol and terbutaline.

#### 7.1.2 Inhaled long-acting beta-2 agonists

The long-acting beta-2 agonists (LABA) are salmeterol and formoterol. LABAs are more effective and more convenient than regular short-acting beta-2 agonists. Their use as monotherapy (without inhaled corticosteroids) appears to be safe (in contrast to asthma). LABAs improve symptoms, reduce exacerbations, reduce rescue therapy requirements and improve exercise capacity (Evidence A).<sup>54</sup> Regular use does not result in loss of efficacy. Formoterol may also be used as reliever treatment because of its rapid onset of action.

#### 7.1.3 Combination of LABA and ICS

A combination of LABA + ICS therapy:

- reduces the number of acute exacerbations in patients with moderate to severe COPD (Evidence A)
- improves FEV1 (Evidence B)
- improves health-related quality of life (Evidence B)
- may increase the risk of pneumonia (Evidence B).<sup>55,56</sup>

Stage 1: Mild	Stage 2: Moderate	Stage 3: Severe	Stage 4: Very severe
Active reduction of risk factors (smoking cessation, influenza vaccination) and rehabilitation.			
Add bronchodilators (short-acting beta-2 agonists or short-acting anticholinergic or both) as needed or regularly and/or oral theophylline.			
		Add regular treatment with long-acting anticholinergic or long-acting beta-2 agonist or both.	
		Add inhaled glucocorticosteroids especially for frequent exacerbations (>2/yr).	
		Add long-term oxygen therapy if chronic respiratory failure.	

Fig. 1. Therapy at each stage of COPD

### 7.1.4 Inhaled anti-cholinergics

Anticholinergic agents are effective bronchodilators for COPD because the disease is associated with increased vagally mediated bronchoconstriction. Ipratropium bromide is a short-acting agent with a peak bronchodilator effect at approximately 40 minutes and between 4 - 6 hours duration of action. Tiotropium bromide is a long-acting anticholinergic with a slow onset of peak bronchodilation but a 24-hour duration of action facilitating once-daily administration. They are more effective than beta-2 agonists in many patients and have fewer side-effects (dry mouth and urinary retention). Ipratropium bromide is prescribed for as-needed use for symptom relief in COPD and can also be used 4 - 6-hourly as a maintenance bronchodilator agent. Tiotropium may be used as a first-line long-acting bronchodilator treatment in COPD or may be used in combination with LABAs because of their different mechanisms of action. Tiotropium has been shown to improve quality of life and reduce exacerbation rates and hospitalisation (Evidence A).<sup>57-60</sup> It is available as a dry powder inhaler and requires an inspiratory flow rate of at least 30 l/min for optimal respiratory tract delivery.

#### 7.1.5 Nebuliser treatment

This is an alternative for Stage 3 and 4 patients with poor inhalation technique and/or acute dyspnoea.

- Nebulised ipratropium plus beta-2 agonist can be used up to 3 or more times daily.<sup>61,62</sup> While there are distinct advantages, nebulisers tend to be overused.
- Patients requiring chronic nebuliser therapy should, where possible, have specialist assessment.

#### 7.1.6 Theophyllines

Theophyllines have similar bronchodilator effects to beta-2 agonists. They improve quality of life, and the oral route of administration is an advantage for some patients.<sup>63</sup> Limitations include toxicity (particularly in the elderly), drug interactions and variable metabolism. The recommended dose of oral slow-release theophylline is 200 - 400 mg twice a day or 400 - 800 mg at night, and should not be exceeded without monitoring blood levels. Combination tablets containing theophylline and other bronchodilators or sedatives are not recommended.

#### 7.1.7 Combination bronchodilator treatment

A combination of bronchodilator agents is recommended and has additive effects. The following combinations are effective:<sup>64,65</sup>

- SABA + ipratropium
- long-acting anti-cholinergic + SABA
- long-acting anti-cholinergic + LABA
- LABA + ipratropium.

Oral theophylline may be added to any combination of inhaled treatment.

### 7.2 Inhaled corticosteroids

Inhaled corticosteroids, particularly in combination with LABAs, have been shown to improve lung function, quality of life and reduce

exacerbations.<sup>55,56</sup> The best evidence for their efficacy is in patients with  $\geq 3$  exacerbations per year, especially in severe disease. Patients need to be carefully monitored for side-effects such as skin bruising and oral candidiasis.

### 7.3 Oral corticosteroids

Oral corticosteroids are no longer recommended for stable COPD.<sup>66</sup> Low-dose oral corticosteroids only cause small improvements in lung function. Higher doses ( $\geq 30$  mg/d) are associated with improvements in lung function but also with major side-effects that include aggravation of blood pressure, hyperglycaemia, decreased adrenal function and osteoporosis. An oral corticosteroid trial is no longer utilised to determine corticosteroid-responsive subjects as such a phenotype cannot be distinguished.<sup>67</sup> It is only recommended in instances where the clinical profile makes distinction between asthma and COPD difficult. A marked improvement in spirometry and symptoms following a corticosteroid trial would suggest asthma.

### 7.4 Newer phosphodiesterase inhibitors

Phosphodiesterase inhibitors, such as Roflumilast, have been shown to be effective in phase III clinical trials but are not yet registered for use in South Africa.

### 7.5 Mucolytics and mucokinetic agents

Expectoration of tenacious sputum is a distressing symptom. Unfortunately, mucolytics, mucokinetic drugs, cough syrups and acetylcysteine (oral and inhaled) have not been shown to be effective, and are not recommended.

### 7.6 Chest physiotherapy

An ineffective cough may be improved by instruction in the 'huff technique' of coughing and active cycle of breathing. Percussion and vibration therapy do not form part of routine management in stable patients. The physiotherapist has an important role in directing the conditioning (exercise) programme and in advising on breathing and coughing techniques.

### 7.7 Venesection

An increased haematocrit causes aggravation of cardiac failure, increased ventilation/perfusion abnormality and an increased incidence of thrombotic episodes. When the haematocrit is  $>0.55$ , therapeutic venesection should be considered; this can be repeated to maintain the haematocrit in the normal range.

### 7.8 Assessment of response to therapy

The FEV<sub>1</sub> is useful as a diagnostic and prognostic tool and is also of value in monitoring disease progression. It is not as useful for assessing response to treatment. Other lung function measurements to monitor response include inspiratory capacity (IC), residual volume (RV) and functional residual capacity (FRC).<sup>68</sup> The response to treatment can also be gauged by the improvement in dyspnoea, and the MRC dyspnoea scale (Table IV) is used to quantify the degree of dyspnoea. The 6-minute walking distance test can be used to assess response to therapy as well. (Appendix B).

## 8. Pulmonary rehabilitation and education (improving quality of life)

Rehabilitation is a team effort involving the doctor, physiotherapist and/or biokineticist. Conditions such as uncontrolled hypertension, and overt or silent cardiac ischaemia, have to be treated before inclusion in a programme.<sup>69-74</sup> Details of a rehabilitation programme

are described in Appendix D. Rehabilitation can be undertaken in resource-limited settings using supervised walking as a major component.

## 9. Prevention and treatment of acute exacerbations of COPD

### 9.1 Definition, natural history and diagnosis of exacerbations

An exacerbation is defined as an increase in symptoms of COPD above the usual day-to-day variation experienced by the patient, and necessitating a change in treatment. Exacerbations vary in both severity and frequency. They tend to become more common as COPD progresses. Exacerbations severely affect quality of life, may be associated with permanent worsening of COPD, account for a large percentage of the direct costs associated with the treatment of COPD, and increase mortality. The most common cause of exacerbations is tracheobronchial infections.

Acute exacerbations must be distinguished from other diseases and complications of COPD (including pneumonia, pneumothorax, congestive heart failure, arrhythmias and pulmonary embolism) that require alternative treatment. When exacerbations are associated with features of infection (pyrexia and purulent sputum), the presence of pneumonia and other forms of lower respiratory infection should be excluded using a chest radiograph. An approach to the antibiotic treatment of acute exacerbations of COPD is provided below (par. 9.3.3) and in Appendix C.

### 9.2 Prevention of exacerbations

The following measures have been shown to reduce the frequency and/or severity of COPD exacerbations (Evidence A):<sup>49,55-57,64,65,73</sup>

- smoking cessation
- prevention of respiratory infections (influenza and pneumococcal vaccination)
- bronchodilator treatment
- inhaled corticosteroids.

### 9.3 Management of exacerbations<sup>1,2,41,45</sup>

#### 9.3.1 Bronchodilators

- Nebulisations with short-acting bronchodilators may be given 4-hourly (or as often as every 30 - 60 minutes or continuously in severe cases). Multiple actuations of an MDI delivered via a large ( $>500$  ml) spacer device may be as effective as nebulisation.
- Should there be an inadequately sustained response to the above treatment, oral or intravenous theophyllines may be used.

#### 9.3.2 Corticosteroids

Corticosteroids should preferably be given orally (Evidence A). A once-daily dose of 30 - 40 mg prednisone is recommended to be continued for 7 - 10 days (Evidence C). Tapering is not required. An equivalent dose of an intravenous steroid may be given if the patient is unable to take oral medication.

#### 9.3.3 Antibiotics (see Appendix C)

These should be prescribed when there is evidence of a severe exacerbation (as evidenced by the 3 cardinal symptoms of increased sputum volume, sputum purulence and increased dyspnoea) or in those who require ventilation (Evidence B). If the patient has 2 of the cardinal symptoms, of which one is increased sputum purulence, they should also receive antibiotics (Evidence C). Sputum Gram-stain may be of help by confirming the presence of relevant organisms, but is not an essential investigation. The organisms most

commonly involved are *Streptococcus pneumoniae*, *Haemophilus influenzae* and *Moraxella catarrhalis*. With the increasing appearance of penicillin- and macrolide-resistant pneumococci, and beta-lactamase-mediated resistance of *H. influenzae* and *M. catarrhalis*, local sensitivity data should be considered when choosing an antibiotic. Macrolides should be avoided in areas where there are high levels of resistance. Alternatives are amoxicillin/clavulanate, cefuroxime, or fluoroquinolones. The oral route of administration is preferred except for severe illness. The duration of treatment should be 5 - 7 days (Evidence A).

### 9.3.4 Oxygen therapy

Oxygen should be started at 24% or 1 - 2 l/minute by nasal cannula. Increases should be gradual to avoid carbon dioxide narcosis. This should be guided by blood gas analysis or by the level of consciousness if blood gases are not available. The aim should be to maintain the saturation above 90%.

### 9.3.5 Physiotherapy to assist with clearance of secretions.

Postural drainage and chest percussion are of limited benefit and can aggravate fatigue and respiratory failure.

### 9.3.6 Indications for hospitalisation

- severe COPD
- any of the following features:
  - sustained failure to improve on outpatient management
  - inability to walk between rooms (where previously mobile)
  - family and/or physician unable to manage the patient at home
  - high-risk co-morbid condition, whether pulmonary (e.g. pneumonia) or non-pulmonary
  - prolonged progressive worsening of symptoms before emergency visit
  - altered mentation
  - worsening hypoxaemia and new or worsening hypercapnia
  - new onset arrhythmia
  - elderly or frail patient
  - new or worsening right-sided cardiac failure unresponsive to outpatient management.

### 9.3.7 Indications for ICU admission

Pre-conditions for ICU admission:

- satisfactory functional status before the exacerbation (patient coped with activities of daily living); if not known, the patient should be given the benefit of the doubt
- possible need for mechanical ventilation i.e. PaO<sub>2</sub> <6.7 kPa (50 mmHg) on room air, arterial blood pH <7.3, and confusion
- the presence of a reversible factor. Examples are infections, bronchospasm, oxygen-induced carbon dioxide narcosis, sedative administration, heart failure or other associated illnesses.

**9.3.8 Ventilatory support** must be considered for the patient with one or more of the following features:

- exhaustion, confusion, coma
- pH <7.3 and declining (respiratory acidosis)
- respiratory or cardiac arrest
- inability to clear secretions.

Modalities of ventilatory support include invasive (mechanical ventilation) and non-invasive continuous positive airways pressure (CPAP) or BiPAP techniques. Patients considered suitable for non-invasive ventilation are those who are able to protect their airway and

clear their airway secretions. Indications for non-invasive ventilation (NIV) include the following (all criteria should be met):

respiratory rate >30 breaths/minute

- pH <7.35
- pCO<sub>2</sub> >6.7 kPa (>50 mmHg)
- paO<sub>2</sub> <6.7 kPa (<50 mmHg) on room air.

Contra-indications to non-invasive ventilation include haemodynamic instability, decreased level of consciousness or poor co-operation, vomiting and excessive secretions. Appearance of any of these features in a patient undergoing NIV who still needs ventilation would be an indication for intubation and mechanical ventilation.

Non-invasive positive pressure ventilation in acute exacerbations has been shown to improve blood gases and pH, reduce in-hospital mortality, decrease the need for invasive mechanical ventilation, and decrease the length of hospital stay (Evidence A).

## 10. Prevention and treatment of complications

The main complications include right heart failure, severe exacerbations, pulmonary embolism, pneumothoraces, erythrocytosis and chronic respiratory failure.

### 10.1 The management of right heart failure

- Identify and treat the precipitating cause. In COPD, this might include an acute respiratory infection, worsening airflow obstruction (review bronchodilator and other treatment) or worsening hypoxaemia from additional factors such as a move to higher altitude or a thrombo-embolic event.
- Correction of hypoxaemia with long-term oxygen as indicated under long-term oxygen therapy (LTOT), see paragraph 6.3) (Evidence D).
- Diuretics (e.g. hydrochlorothiazide 25 mg or equivalent). Avoid large decreases in preload which may precipitate hypotension and renal impairment.
- Digoxin must be avoided except in the presence of atrial fibrillation and/or left ventricular dysfunction/failure (Evidence C).
- ACE inhibitors and calcium antagonists are not indicated for the management of cor pulmonale or right ventricular failure (Evidence B).
- Prophylaxis with subcutaneous heparin to prevent deep vein thrombosis during periods of exacerbation or prolonged immobilisation (Evidence A).
- Chronic treatment with warfarin needs to be considered in COPD patients with atrial fibrillation or thrombo-embolic complications (Evidence A). There is no evidence of benefit when used routinely in patients with cor pulmonale secondary to COPD (Evidence C).

### 10.2 Pneumothorax

The development of a spontaneous pneumothorax must be considered when patients with stable COPD suddenly deteriorate, as patients with respiratory impairment tolerate even a small pneumothorax poorly.

### 10.3 Long-term oxygen therapy (LTOT)

The full benefit is only evident in patients with persistent hypoxaemia (with or without hypercapnia) in the stable phase of COPD. In such patients, it has been shown to reduce the complications of respiratory and right heart failure and to improve survival.

#### 10.3.1 Indications for LTOT

- Stable, severe COPD (usually but not exclusively with an FEV<sub>1</sub> <1.5 l and FEV<sub>1</sub>/FVC <70%) on optimal bronchodilator therapy.

The decision to prescribe LTOT should only be made once the patient has fully recovered from an acute exacerbation ( usually after 6 weeks).

- Arterial hypoxaemia ( $\text{PaO}_2 < 7.3 \text{ kPa}$  or  $55 \text{ mmHg}$  at sea-level) or oxygen saturation  $< 90\%$  at rest.
- Smoking cessation for  $\geq 3$  months.

Hypoxaemia must be confirmed by arterial blood gases performed while the patient is breathing room air. Following exacerbations of COPD, spirometry and  $\text{PaO}_2$  may continue to improve for up to 3 months. Therefore, these should ideally be checked in all patients on 2 occasions at least 1 month, and preferably 3 months, apart before prescribing LTOT. Continued smoking reduces the efficacy of treatment and is a contra-indication to oxygen therapy. Worsening hypercapnia caused by hypoventilation is an occasional complication of oxygen therapy in patients with severe COPD and hypercapnic respiratory failure. Regular follow-up by a suitably experienced physician and ready access to technical advice, either through a private contractor or a hospital department, must be available. Assessment of adherence is essential.

### 10.3.2 Oxygen prescription

Oxygen is administered by facemask or nasal cannula for a total of at least 16 hours per 24-hour day. A flow rate of 1 - 2 l/minute is used, the rate being determined in each case by arterial blood gas determinations. Oximetry may be used for follow-up checks. Oxygen can be delivered by oxygen concentrators or by cylinders. Concentrators are more convenient and cost effective. Portable oxygen systems include bottled oxygen with flow-saving devices and portable concentrators. With these systems, patients do not have to be confined to home.

### 10.4 Palliative symptomatic oxygen therapy

Oxygen given for short periods to relieve breathlessness in hypoxic patients with COPD does not influence the natural progression of the disease and is therefore not routinely recommended. Patients in whom a fall in  $\text{PaO}_2$  occurs during exercise may improve their exercise capacity with supplemental oxygen. Patients who desaturate at night should be assessed for sleep apnoea and treated appropriately.

## 10.5 Additional considerations

### 10.5.1. Sleep in COPD

Sleep is associated with a decrease in arterial oxygen saturation ( $\text{SaO}_2$ ) in most individuals that is more marked in COPD. Significant night-time hypoxaemia cannot be predicted from measurement of daytime blood gas and pulmonary function tests, but if the daytime  $\text{PaO}_2$  is  $\geq 8 \text{ kPa}$ , nocturnal  $\text{SaO}_2$  need only be measured if unexplained respiratory failure, cor pulmonale or erythrocytosis are found. Referral for a full sleep study (polysomnography) and a specialised opinion should only be considered if sleep-disordered breathing is suspected (i.e. daytime hyper-somnolence and other symptoms of sleep deprivation, or a strong history of loud snoring with apnoeic events). Long-term oxygen therapy, prescribed for daytime hypoxaemia, must be used during sleep.

### 10.5.2. Surgery for COPD

Surgical techniques that can improve lung function and symptoms of COPD include:

- bullectomy
- lung volume reduction surgery
- lung transplantation.

### Bullectomy

This may be indicated to decompress adjacent lung parenchyma if there are large localised bullae. This can be performed thoracoscopically, and may reduce dyspnoea and improve lung function (Evidence C).

### Lung volume reduction surgery (LVRS)

In this procedure, parts of the lung are resected to reduce hyperinflation. It is an alternative to lung transplantation in patients with severe inhomogeneous emphysema who remain symptomatic despite optimal medical therapy. The  $\text{FEV}_1$  improves by about 10% with larger improvements in exercise tolerance, dyspnoea and quality of life.

The ideal candidate should be carefully selected by a multi-disciplinary team including the general practitioner, pulmonologist and thoracic surgeon. Guidelines include a  $\text{FEV}_1$  20 - 35% of that predicted, diffusion capacity for carbon monoxide  $> 20\%$  predicted, hyperinflation with inhomogeneous disease and limited co-morbidities. In experienced units, survival after 4 years is 54% v. 39.7% for medical therapy in patients with mainly upper lobe emphysema and low exercise capacity. LVRS remains an expensive palliative surgical procedure and is recommended only in carefully selected patients. New techniques to effect LVR using valves or biological substances are being investigated.

### Lung transplantation

This approach may be used in patients with diffuse severe emphysema, but access to transplantation is severely limited in South Africa. Its effect on survival after 2 years remains controversial. General guidelines recommend that the patient must be  $< 65$  years old without any other medical condition that could shorten predicted survival. Additional criteria for referral include  $\text{FEV}_1 < 35\%$  predicted,  $\text{PaO}_2 < 7.3 - 8.0 \text{ kPa}$ ,  $\text{PaCO}_2 > 6.7 \text{ kPa}$  and secondary pulmonary hypertension.

### 10.5.3 Surgery in COPD

Post-operative pulmonary complications constitute a significant cause of morbidity and mortality. The frequency varies from 2 - 70%. The complications are atelectasis, infection (bronchitis and pneumonia), respiratory failure necessitating prolonged mechanical ventilation, exacerbation of COPD, bronchospasm and pulmonary embolism. Stratification of risk for pulmonary complications entails patient-related as well as procedure-related risk factors. Preoperative evaluation depends strongly on taking a thorough history and clinical examination. It is reasonable to perform a preoperative chest radiograph in patients with cardiopulmonary disease and those  $> 50$  years undergoing high-risk surgery. Pre-operative preparation, optimisation of airway function (bronchodilators, steroids, antibiotics and chest physiotherapy), smoking cessation, weight reduction where applicable, delay of elective surgery if chest infection is present, and patient education on deep breathing exercises, coughing, pain control and incentive spirometry are recommended. Post-operative measures include early mobilisation and ambulation, prophylactic lung expansion manoeuvres, adequate analgesia and prophylaxis against thrombosis.

### 10.5.4 Spacer devices and delivery methods

The use of spacer devices may improve delivery of medication to the lower airways in patients with poor inhaler technique and poor lung function. Some patients may achieve better results with dry powder devices. It is vital to ensure that the individual uses the inhaler device correctly.

### 10.5.5 Air travel

COPD patients who travel by commercial aircraft put themselves at risk for a range of complications. Respiratory incidents comprise 9 - 10% of airborne emergencies. Therefore the need to travel needs to be balanced against the potential risks. Potential travelers with COPD should have stable disease (no recent exacerbations, hospitalisations or acute illnesses). Co-morbid disease increases the risks of in-flight emergencies i.e. ischaemic heart disease, congestive cardiac failure and cor pulmonale (56% of all in-flight emergencies). Potential problems include:

- hypoxaemia at altitude: stable COPD patients with an oxygen saturation (SaO<sub>2</sub>) of 95% preflight desaturate to about 86% at a cabin altitude of 2 165 m. This worsens to 78% with activity.
- worsening of existing hypoxia at ground level
- pulmonary hypertension
- worsening discomfort and dyspnoea at altitude
- cardiac dysrhythmias
- risk of contracting a respiratory infection
- pneumothorax from large bullae.

The most practical evaluation includes room air SaO<sub>2</sub> measurements pre-flight. If the SaO<sub>2</sub> is less than 92%, further assessment is necessary. Available tests are :

- 50 m walk test. Those who desaturate will require supplemental O<sub>2</sub>.
- Hypoxic inhalation test. Patients breathe 15% FiO<sub>2</sub> at sea level. Those with significant desaturation will need supplemental O<sub>2</sub>.
- hypobaric chamber simulating in-flight conditions .Their limited availability precludes widespread use in assessing patients. The in-flight requirement would be 2 l/min higher than home use, or 2 - 4 l/minute if the assessment indicates the need for O<sub>2</sub>.

### Acknowledgements

Several components of this guideline represent an unchanged standard of care and are based on the previous edition of the South African Guideline of which Professor E D Bateman was the chief author; his contribution is gratefully acknowledged.

### References

1. Bateman ED, Feldman C, O'Brien J, Joubert JR. Guideline for the Management of COPD: 2004 revision. *S Afr Med J* 2004;94:559-575.
2. Rodriguez-Roisin R, Rabe KF, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda, MD: NHLBI, 2008. <http://www.goldcopd.com> (accessed 4 May 2009).
3. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. *Eur Respir J* 2006;27:397-412.
4. Celli BR. Update on the management of COPD. *Chest* 2008;133:1451-1462.
5. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. *Eur Respir J* 2006;28:523-532.
6. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. *Lancet* 2007;370:741-750.
7. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. *Lancet* 1997;349:1498-1504.
8. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. *JAMA* 2005;294:1255-1259.
9. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. *Lancet* 2005;365:2225-2236.
10. McCloskey SC, Patel BD, Hinchliffe SJ, et al. Siblings of patients with severe chronic obstructive pulmonary disease have a significant risk of airflow obstruction. *Am J Respir Crit Care Med* 2001;164:1419-1424.
11. Ammous Z, Hackett NR, Butler MW, et al. Variability in small airway epithelial gene expression among normal smokers. *Chest* 2008;133:1344-1353.
12. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. *Eur Respir J* 2006;28:523-532.
13. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. *MMWR Surveill Summ* 2002;51:1-16.
14. Silverman EK, Weiss ST, Drazen JM, et al. Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000;162:2152-2158.
15. Barker DJ, Godfrey KM, Fall C, Osmond C, Winter PD, Shaheen SO. Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. *Br Med J* 1991;303:671-675.
16. Lawlor DA, Ebrahim S, Davey Smith G. Association of birth weight with adult lung function: findings from the British Women's Heart and Health Study and a meta-analysis. *Thorax* 2005;60:851-858.
17. Burrows B, Knudson RJ, Cling ME, Lebowitz MD. Quantitative relationships between cigarette smoking and ventilatory function. *Am Rev Respir Dis* 1977;115:195-205.
18. Fletcher C, Peto R. The natural history of chronic airflow obstruction. *Br Med J* 1977;1:1645-1648.
19. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. *Am J Respir Crit Care Med* 2002;166:675-679.
20. Rennard S, Vestbo J. COPD: the dangerous underestimate of 15%. *Lancet* 2006;367:1216-1219.
21. Eisner MD, Balmes J, Katz BP, Trupin L, Yelin E, Blanc P. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. *Environ Health Perspect* 2005;4:7-15.
22. Dayal HH, Khuder S, Sharrar R, Trieff N. Passive smoking in obstructive respiratory disease in an industrialized urban population. *Environ Res* 1994;65:161-171.
23. Tager IB, Ngo L, Hanrahan JP. Maternal smoking during pregnancy. Effects on lung function during the first 18 months of life. *Am J Respir Crit Care Med* 1995;152:77-83.
24. Tashkin DP. Does cannabis use predispose to chronic airflow obstruction? *Eur Respir J* 2010;35:3-5.
25. Becklake MR. Occupational exposures: evidence for a causal association with chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1989;140:85-91.
26. Hnizdo E, Sullivan PA, Bang KM, Wagner G. Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey. *Am J Epidemiol* 2002;156:738-746.
27. Jaakkola MS, Jaakkola JK. Biomass fuels and health. *Am J Respir Crit Care Med* 2006;174:851-852.
28. Ezzati M. Indoor air pollution and health in developing countries. *Lancet* 2005;366:104-106.
29. Regalado J, Perez-Padilla R, Sansores R, et al. The effect of biomass burning on respiratory symptoms and lung function in rural Mexican women. *Am J Respir Crit Care Med* 2006;174:901-905.
30. Liu S, Zhou Y, Wang X, et al. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. *Thorax* 2007;62:889-897.
31. Dennis RJ, Maldonado D, Norman S, Baena E, Martinez G. Woodsmoke exposure and risk for obstructive airways disease among women. *Chest* 1996;109:115-1192.
32. Orozco-Levi M, Garcia-Aymerich J, Villar J, Ramirez-Sarmiento A, Anto JM, Gea J. Wood smoke exposure and risk of chronic obstructive pulmonary disease. *Eur Respir J* 2006; 27:542-546.
33. Sezer H, Akkurt I, Guler N, Marakoglu K, Berk S. A case-control study on the effect of exposure to different substances on the development of COPD. *Ann Epidemiol* 2006;16:59-62.
34. Abbey DE, Burchette RJ, Knutsen SF, McDonnell WF, Lebowitz MD, Enright PL. Long-term particulate and other air pollutants and lung function in non-smokers. *Am J Respir Crit Care Med* 1998;158:289-298.
35. Shaheen SO, Barker DJ, Shiell AW, Crocker FJ, Wield GA, Holgate ST. The relationship between pneumonia in early childhood and impaired lung function in late adult life. *Am J Respir Crit Care Med* 1994;149:616-619.
36. Pasipanodya JG, Miller TL, Vecino M, et al. Pulmonary impairment after tuberculosis. *Chest* 2007;131:1817-1824.
37. Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment by initial and recurrent pulmonary tuberculosis following treatment. *Thorax* 2000;55:32-38.
38. Long R, Maycher B, Dhar A, et al. Pulmonary tuberculosis treated with directly observed therapy: serial changes in lung structure and function. *Chest* 1998;113:933-943.
39. de Valiere S, Barker RD. Residual lung damage after completion of treatment for multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis* 2004;8:767-771.
40. Diaz PT, King MA, Pacht ER, et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. *Ann Intern Med* 2000;132:369-372.
41. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001;164:1618-1623.
42. Prescott E, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. *Eur Respir J* 1999;13:1109-1114.
43. Coxson HO, Chan IH, Mayo JR, Hlynsky J, Nakano Y, Birmingham CL. Early emphysema in patients with anorexia nervosa. *Am J Respir Crit Care Med* 2004;170:748-752.
44. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J* 2004; 23: 932-946.
45. National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. *Thorax* 2004;59 Suppl 1:1-232.
46. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, european community for steel and coal. Official statement of the European Respiratory Society. *Eur Respir J Suppl* 1993;16:5.
47. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. *Am J Respir Crit Care Med* 1999;159:179-187.
48. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med* 2004;350:1005-1012.
49. Tonnesen. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. *Eur Respir J* 2007;29:390-417.
50. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. *Am J Prev Med* 2008;35:158-176.
51. Ikeda A, Nishimura K, Koyama H, Izumi T. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone. *Chest* 1995;107(2):401-405.
52. Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. *Chest* 1999;115:635.
53. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1996;153:967-975.
54. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. *Chest* 1999;115:957-965.
55. Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. *COPD* 2009;6:320-329.
56. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med* 2007;356:775-789.
57. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. *Eur Respir J* 2002;19:209-216.
58. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. *Eur Respir J* 2004;23:832.
59. Anzueto A, Tashkin D, Menjoge S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. *Pulm Pharmacol Ther* 2005;18:75.
60. Van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. *Eur Respir J* 2005;26:214.
61. Moayyedi P, Conleton J, Page RL, Pearson SB, Muers MF. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. *Thorax* 1995;50:834-837.
62. Gross N, Tashkin D, Miller R, et al. Inhalation by nebulization of albuterol-ipratropium combination [Dey combination] is superior to either agent in the treatment of chronic obstructive pulmonary disease. *Respiration* 1998;65:354.

63. Ram, FS, Jones, PW, Castro, AA, et al. Oral theophylline for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2002; CD003902.
64. Aaron SD, Vandemheen KL, Ferguson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. *Ann Intern Med* 2007;146:545.
65. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. *N Engl J Med*. 2008;359:1543-1554.
66. Walters JAE, Walter EH, Wood-Baker R. Oral Corticosteroids for stable COPD. *Cochrane Database of Systematic Reviews* 2005. CD 005374.
67. Burge S, Calverly PMA, Jones PW, Spencer S, Anderson JA. Prednisolone response in patients with COPD: results from ISOLDE. *Thorax* 2003;58:654-658.
68. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. *Am J Resp. Crit Care Med* 2001;163:1395-1399.
69. Mohsenifar Z, Lee SM, Diaz P, et al. Single-breath diffusing capacity of the lung for carbon monoxide. A predictor of PaO<sub>2</sub>, maximum work rate and walking distance in patients with emphysema. *Chest* 2003;123:1394-1400.
70. De Klerk D. An adapted rehabilitation program for a cross section of South African chronic obstructive pulmonary disease patients. PhD thesis, Faculty of Sport Science, Stellenbosch University, 2008.
71. Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S. Improvement of exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. *Chest* 2005;127: 809-817.
72. Peters MM, Webb KA, O'Donnell DE. Combined physiological effects of bronchodilators and hyperoxia on exertional dyspnoea in normoxic COPD. *Thorax* 2006;61:559-567.
73. Garcia-Aymerich, Lange P, Benet M, Schinohr P, Antó JM. Regular physical activity reduces hospital admissions and mortality in chronic obstructive pulmonary disease: a population based cohort study. *Thorax* 2006;61:772-778.
74. Morgan MD. Preventing hospital admissions for COPD: role of physical activity. *Thorax* 2003;58:95-96.
75. ATS statement. Guidelines for the six-minute walk test. *Am J Resp Crit Care Med* 2002;166:111-117.

Accepted 14 September 2010.

## Appendix A

### Process of guideline revision

In 2008, the Council of the South African Thoracic Society resolved to revise the 2004 COPD guideline and appointed a convenor (Dr Abdool-Gaffar) and editorial committee, selected a review date and agreed on the process of revision. Membership of the Working Group comprised most members of the previous working group and general practitioners. The editorial committee identified areas of the guideline that required revision and commissioned members of the working group to prepare reviews of new data in these areas, with particular reference to the content of the latest version of the Global Obstructive Lung Disease Guideline. The workshop was held in August 2008. A draft revision document, based on the consensus obtained at the workshop, was compiled by the editorial board, and circulated to the guideline committee for further comment in 2009. These comments were considered by the editorial committee, and the final draft was then completed and approved by the Council of the South African Thoracic Society by postal vote in May 2010.

## Appendix B

### The 6-minute walk test (6MWT)<sup>75</sup>

The 6MWT is a composite and repeatable test of lung, heart and muscle function. Measurement of specific exercise-induced outcomes are an extremely important adjunct to clinical and lung function evaluation. The 6MWT does not correlate well with FEV<sub>1</sub> but relates to the degree of exercise-induced hyperinflation of COPD patients, and is used extensively as a prognostic indicator for patients with COPD, interstitial lung disease or pulmonary hypertension. It provides better insight into the degree of exercise impairment compared with single evaluations such as spirometry or an ECG.

The 6MWT has to be conducted under supervision of a trained medical or paramedical person who can recognise untoward exercise-induced symptoms. Prior to the test, patients have to be evaluated to rule out uncontrolled hypertension, ischaemic heart disease, arrhythmias and heart failure that may complicate the assessment or endanger the patient. These conditions need adequate treatment

before the 6MWT can be conducted. Patients with lower limb arthritis or claudication and those who are mentally challenged or old and infirm will not perform the test adequately. It can be conducted in any facility that has the necessary resuscitation equipment and a straight, flat surface of 30 meters or a treadmill. Prior to the test, patients need to be counseled to motivate them to achieve the greatest distance. They also need to be informed that they may rest during the test but that it will be recorded as part of their 6MWT walk time. All COPD patients need to use their bronchodilators before attempting the 6MWT, and they should not be exercised during an infective episode or if they are in the immediate recovery phase of an exacerbation.

0	Nothing at all
1	Very slight
2	Slight
3	Moderate
4	Somewhat severe
5	Severe
6	
7	Very severe
8	
9	Very, very severe (almost maximal)
10	Maximal

Fig. 2. 10-point Borg Category Scale of dyspnoea and fatigue

A baseline ECG is done and should be repeated after the first effort to record any asymptomatic exercise-induced ischaemic changes. The oxygen saturation of blood should be measured before and after the test. Determination of pulse rate, blood pressure and respiratory rate along with the blood oxygen saturation level should be recorded before and after the test. A level in the latter <90% or a decline >5% will identify those patients who will require oxygen during the test. Patients' opinions as to their degree of exhaustion need to be recorded on a Borg scale card (Fig. 2) which provides a semi-quantitative estimation of fatigue and dyspnoea. Recovery time should be noted by measuring the respiratory and heart rates at 3 and 5 minutes after the test. Repeatability of the 6MWT (distance) of 10% should be achieved. In this respect, a second or, if required, even a third 6MWT should be conducted after periods of rest of up to 20 minutes. The 6MWT should be discontinued in patients who complain of chest pain, intolerable dyspnoea or leg cramps, or appear to be staggering or have an ashen or pale appearance. A mean value for males of 464 metres and 430 metres for females is the standard for a healthy American population. A post-intervention improvement of 54 meters above the baseline 6MWT has been found to represent a clinically meaningful improvement in COPD patients who undergo rehabilitation.

## Appendix C

### Antibiotic use in exacerbations of COPD

Chronic bronchitis, with attendant mucociliary dysfunction and mucus hypersecretion, is the major pathological component that is responsible for the risk of bacterial colonisation and acute infective exacerbations of COPD.

### Recommendations for the antibiotic management of acute exacerbations of COPD based on a classification of bronchitis

Diagnosis	Criteria/risk factors	Usual pathogens	Recommended treatment*
1. Simple chronic bronchitis	<ul style="list-style-type: none"> <li>• Younger patient</li> <li>• FEV<sub>1</sub> &gt;60% predicted</li> <li>• Recent increase in sputum volume and purulence</li> </ul>	<ul style="list-style-type: none"> <li>• <i>H. influenzae</i></li> <li>• <i>M. catarrhalis</i></li> <li>• <i>S. pneumoniae</i> acid</li> <li>• Beta-lactam resistance possible</li> </ul>	<ul style="list-style-type: none"> <li>• Aminopenicillin</li> <li>• Amoxycillin-clavulanic</li> <li>• Macrolide/azalide/Ketolide</li> </ul>
2. Complicated chronic bronchitis	<ul style="list-style-type: none"> <li>• Older age</li> <li>• FEV<sub>1</sub> &lt; 60% predicted</li> <li>• &gt;4 exacerbations/year</li> <li>• Recent increase in sputum volume and purulence</li> </ul>	<ul style="list-style-type: none"> <li>• Same organisms as in 1, but beta-lactam resistance more common</li> <li>• Sputum Gram stain and culture advised</li> </ul>	<ul style="list-style-type: none"> <li>• Amoxycillin-clavulanic acid</li> <li>• Second or third generation cephalosporin</li> <li>• Respiratory fluoroquinolone</li> </ul>
3. Complicated chronic bronchitis with chronic bronchial sepsis.	<ul style="list-style-type: none"> <li>• As above with purulent sputum for long periods in year</li> <li>• X-ray evidence of structural lung disease</li> </ul>	<ul style="list-style-type: none"> <li>• Same as 2, but also Enterobacteriaceae and <i>Pseudomonas aeruginosa</i></li> <li>• Sputum Gram stain and culture advised</li> </ul>	<ul style="list-style-type: none"> <li>• Ciprofloxacin or</li> <li>• Respiratory fluoroquinolone</li> <li>• Alternative based on result of sputum culture</li> </ul>

\* Selection of antibiotic is influenced by knowledge of antibiotic resistance patterns in different areas of the country.  
 \*\*Adapted from Grossman RF. The value of antibiotics and the outcomes of antibiotic therapy in exacerbations of COPD. Chest 1998;113:249-255.

## Appendix D

### Pulmonary rehabilitation

Rehabilitation is a team effort in which the doctor, a physiotherapist or biokineticist motivate patients to achieve an exercise-orientated lifestyle. All COPD patients who are dyspnoeic, regardless of their measured FEV<sub>1</sub>, qualify for the rehabilitation process. Factors such as exercise-induced hypoxia and exercise-induced hyperinflation in subsets of COPD patients aggravate the muscle weakness and enhance the level of dyspnoea.

A thorough pre-rehabilitation evaluation needs to be done by an appropriately experienced doctor. Three aspects should be considered:

- The first is to identify individuals who should be temporarily precluded from the rehabilitation programme. Conditions such as uncontrolled hypertension and overt or silent cardiac ischaemia that may cause heart failure have to be treated before inclusion. Additionally, those who have acute lower respiratory tract infections or arrhythmias will first require treatment for their immediate illness.
- Secondly, the evaluation should include a baseline measurement of cardiac and lung function such as spirometry, dyspnoea assessment as well as a baseline 6MWT. These measurements will serve as points of reference for comparison during and after the rehabilitation process.
- A third important aspect of the evaluation is explaining the rehabilitation process, emphasising the goals that need to be achieved and general motivation to achieve the best outcome.

Rehabilitation improves exercise capacity, reduces perceived dyspnoea during exertion, enhances the health-related quality of life and reduces the number of hospitalisations and days in hospital.

Patients should be prepared for at least 25 rehabilitation sessions of one hour each under the guidance of a trained staff member. The sessions should be conducted at a tempo of 2 - 3 per week. Goal-setting and motivation should be maintained throughout to retain the advantages achieved during the programme. The programme should include balanced endurance and muscle strengthening exercises with emphasis on the thigh, shoulder and respiratory muscles. The rehabilitation process complements and enhances quality of life, dyspnoea improvement and exercise tolerance to a greater extent than pharmacological treatment alone. Patients who initially desaturate during the pre-rehabilitation evaluation should not be excluded. If their O<sub>2</sub> saturation drops below 90%, the rehabilitation programme should be conducted with the patient on oxygen.

In a South African study,<sup>70</sup> individuals who underwent rehabilitation predominantly in the open air under professional supervision improved their 6MWT, quality of life estimation and degree of dyspnoea to the same extent as a group of patients who had been rehabilitated in a fully equipped gymnasium. The importance of maintaining a long-term exercise programme for COPD patients to lower their risk for hospital admission and death has been established. In this context, the post-rehabilitation evaluation conducted by the referring physician, during which the 6MWT and dyspnoea calculation is repeated and compared with the pre-rehabilitation values, can be extremely rewarding for patients. Regular enquiry and motivation by the doctor during the long-term follow-up is required to keep patients from slipping back into an inactive lifestyle.

# NOTES

# NOTES

# NOTES